A STUDY OF CYTOKINE PRODUCTION IN ACUTE GRAFT-VS-HOST DISEASE

被引:41
|
作者
SMITH, SR
TERMINELLI, C
KENWORTHYBOTT, L
PHILLIPS, DL
机构
[1] Department of Allergy and Immunology, Schering-Plough Research, Bloomfteld
关键词
D O I
10.1016/0008-8749(91)90307-W
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The role of cytokines in the development of acute graft-vs-host disease (GVHD) was investigated in B6AF1 mice that were injected with parental A/J lymphocytes. Splenocytes from GVH mice exhibited an increased capacity to produce interleukin (IL)-1, IL-6, and TNF-α when stimulated in culture with lipopolysaccharide (LPS). This enhanced capacity was diminished following in vivo treatment with immunosuppressive drugs. Concanavalin A-stimulated GVH spleen cells produced significantly lower levels of IL-2 but higher levels of interferon-γ (IFN-γ) than did syngeneic spleen cells. Immunosuppressive therapy in vivo increased the capacity of GVH spleen cells to produce IL-2. However, immunosuppremants differed in their effects on IFN-γ production. Sch 24937 (6-bromo-5-chloro-2-[1-(methysulfonyl)acetyl] 3-(2-pyridyl)indole) enhanced or had no effect while cyclosporin A consistently decreased the capacity of splenocytes to produce this lymphokine. These results indicate that the capacity of GVH splenocytes for cytokine production can be differentially affected by the actions of some pharmacological agents. The data also indicate that there may be differential regulation of the production of IL-2 and IFN-γ by the Th1 subset in the GVH spleen. © 1991.
引用
下载
收藏
页码:336 / 348
页数:13
相关论文
共 50 条
  • [21] SYNGENEIC GRAFT-VS-HOST DISEASE
    FERRARA, JLM
    ARCHIVES OF DERMATOLOGY, 1987, 123 (06) : 741 - 742
  • [22] Eczematoid graft-vs-host disease
    Cook-Norris, Robert H.
    Weenig, Roger H.
    ARCHIVES OF DERMATOLOGY, 2008, 144 (08) : 1066 - 1066
  • [23] BIOLOGY OF GRAFT-VS-HOST DISEASE
    KORNGOLD, R
    AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1993, 15 (01): : 18 - 27
  • [24] ELEVATED INFLAMMATORY CYTOKINE LEVELS IN CHRONIC GRAFT-VS-HOST DISEASE (CGVHD)
    NAGLER, A
    LEVISCHAFFER, F
    KALICKMAN, I
    BARAK, V
    EXPERIMENTAL HEMATOLOGY, 1994, 22 (08) : 803 - 803
  • [25] Phase II study of daclizumab for treatment of acute graft-vs-host disease.
    Przepiorka, D
    Kernan, N
    Ippoliti, C
    Papadopoulos, E
    Giralt, S
    Khouri, I
    Lu, J
    Gajewski, J
    Durett, A
    Cleary, R
    Champlin, R
    Andersson, B
    Light, S
    EXPERIMENTAL HEMATOLOGY, 1998, 26 (08) : 691 - 691
  • [26] A retrospective study of acute graft-vs-host disease and its mimickers in the posttransplant period
    Calhoun, Cody
    Stallman, Eunice
    Jaglowksi, Samantha
    Kaffenberger, Benjamin H.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (08) : E299 - E301
  • [27] Extracellular vesicles as potential biomarkers of acute graft-vs-host disease
    G Lia
    L Brunello
    S Bruno
    A Carpanetto
    P Omedè
    M Festuccia
    L Tosti
    E Maffini
    L Giaccone
    M Arpinati
    G Ciccone
    M Boccadoro
    A Evangelista
    G Camussi
    B Bruno
    Leukemia, 2018, 32 : 765 - 773
  • [28] RISK-FACTORS FOR ACUTE GRAFT-VS-HOST DISEASE (GVHD)
    BORTIN, MM
    EXPERIMENTAL HEMATOLOGY, 1985, 13 (05) : 406 - 406
  • [29] RECTAL BIOPSY DIAGNOSIS OF ACUTE GRAFT-VS-HOST DISEASE IN MAN
    EPSTEIN, RJ
    MCDONALD, GB
    SALE, GE
    GASTROENTEROLOGY, 1979, 76 (05) : 1128 - 1128
  • [30] Extracellular vesicles as potential biomarkers of acute graft-vs-host disease
    Lia, G.
    Brunello, L.
    Bruno, S.
    Carpanetto, A.
    Omede, P.
    Festuccia, M.
    Tosti, L.
    Maffini, E.
    Giaccone, L.
    Arpinati, M.
    Ciccone, G.
    Boccadoro, M.
    Evangelista, A.
    Camussi, G.
    Bruno, B.
    LEUKEMIA, 2018, 32 (03) : 765 - 773